Myocarditis; This literature-non-study case was reported in a literature article and describes the occurrence of MYOCARDITIS (Myocarditis) in a 20-year-old female patient who received mRNA-1273 (Spikevax) for COVID-19 vaccination.      The patient's past medical history included COVID-19 (5 months prior to admission). Concurrent medical conditions included Depression.    On an unknown date, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced MYOCARDITIS (Myocarditis) (seriousness criterion medically significant). At the time of the report, MYOCARDITIS (Myocarditis) had resolved. Related    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Culture: normal (normal) normal. On an unknown date, Echocardiogram: normal (normal) normal. On an unknown date, Electrocardiogram: pr depression (abnormal) PR depression. On an unknown date, Fibrin D dimer: high (High) High. On an unknown date, Magnetic resonance imaging heart: consistent with myocarditis (abnormal) consistent with myocarditis. On an unknown date, Red blood cell sedimentation rate: high (High) High. On an unknown date, Respiratory viral panel: normal (normal) normal. On an unknown date, Troponin: high (High) High. On an unknown date, Viral test: negative (Negative) Negative.     The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown.   For mRNA-1273 (Spikevax) (Unknown), the reporter considered MYOCARDITIS (Myocarditis) to be related.    No concomitant medications were reported.  This article reported 20-year-old female presented with progressive pleuritic chest pain and fever after Moderna mRNA vaccine. Also, the patient was treated with supportive care and her condition improved.  Company Comment: This is a Literature-Non-Study case concerning a 20-year-old female patient, with reported medical history of COVID-19 (with an unknown outcome), who experienced the serious expected AESI of Myocarditis. The event occurred in an unknown exact date, one week after the administration of the first dose of the mRNA-1273 vaccine. In this case, there is reported that the patient was "admitted", but there is limited information, hence the event is considered as serious due to an Important Medical event and not for hospitalization. The reported medical history remains as a possible contributor for the event. Relevant tests were performed that showed elevated D-dimer, erythrocyte sedimentation rate (ESR), and troponin levels. Electrocardiogram showed PR depression. Echocardiogram, respiratory viral panels, and cultures were normal and cardiac magnetic resonance imaging (CMRI), which was consistent with myocarditis. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report. The case was assessed as serious.; Sender's Comments: This is a Literature-Non-Study case concerning a 20-year-old female patient, with reported medical history of COVID-19 (with an unknown outcome), who experienced the serious expected AESI of Myocarditis. The event occurred in an unknown exact date, one week after the administration of the first dose of the mRNA-1273 vaccine. In this case, there is reported that the patient was "admitted", but there is limited information, hence the event is considered as serious due to an Important Medical event and not for hospitalization. The reported medical history remains as a possible contributor for the event. Relevant tests were performed that showed elevated D-dimer, erythrocyte sedimentation rate (ESR), and troponin levels. Electrocardiogram showed PR depression. Echocardiogram, respiratory viral panels, and cultures were normal and cardiac magnetic resonance imaging (CMRI), which was consistent with myocarditis. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report. The case was assessed as serious.